© Copyright 2025 American Medical Association. All rights reserved.
The CPT® Code 81427 pertains to the re-evaluation of previously obtained genome sequences, specifically in the context of unexplained constitutional or heritable disorders or syndromes. This procedure is essential for patients who may have undergone initial genome sequencing but require further analysis due to advancements in genetic knowledge or the emergence of unrelated conditions or syndromes. Molecular genetic testing, as described, involves a comprehensive examination of both coding and non-coding DNA sequences, which are crucial for understanding genetic variations that may contribute to various health conditions. Whole genome sequencing (WGS) serves as a powerful tool in identifying rare genetic disorders, particularly in patients exhibiting atypical symptoms or characteristics. Additionally, it can be utilized by healthy individuals to determine carrier status for familial diseases or to assess predispositions to adult-onset medical conditions. The process begins with the collection of a blood sample through a separately reportable venipuncture, followed by DNA analysis using next-generation sequencing techniques. This code is particularly relevant when there is a need to revisit and interpret previously gathered genomic data in light of new scientific insights or when a patient presents with a different, unrelated genetic condition.
© Copyright 2025 Coding Ahead. All rights reserved.
The indications for utilizing CPT® Code 81427 include the following:
The procedure associated with CPT® Code 81427 involves several key steps that ensure a thorough re-evaluation of the previously obtained genome sequence:
After the re-evaluation procedure associated with CPT® Code 81427, patients may receive a report detailing the findings from the genomic analysis. It is important for healthcare providers to discuss these results with the patient, as they may have implications for diagnosis, treatment options, or family planning. Additionally, follow-up consultations may be necessary to address any new information that arises from the re-evaluation, particularly if it relates to the management of a heritable disorder or syndrome. Patients should also be informed about the potential for further testing or referrals to genetic counseling services if new genetic risks are identified.
Short Descr | GENOME RE-EVALUATION | Medium Descr | GENOME RE-EVALUATION OF PREC OBTAINED GENOME SEQ | Long Descr | Genome (eg, unexplained constitutional or heritable disorder or syndrome); re-evaluation of previously obtained genome sequence (eg, updated knowledge or unrelated condition/syndrome) | Status Code | Statutory Exclusion (from MPFS, may be paid under other methodologies) | Global Days | XXX - Global Concept Does Not Apply | PC/TC Indicator (26, TC) | 9 - Not Applicable | Multiple Procedures (51) | 9 - Concept does not apply. | Bilateral Surgery (50) | 9 - Concept does not apply. | Physician Supervisions | 09 - Concept does not apply. | Assistant Surgeon (80, 82) | 9 - Concept does not apply. | Co-Surgeons (62) | 9 - Concept does not apply. | Team Surgery (66) | 9 - Concept does not apply. | Diagnostic Imaging Family | 99 - Concept Does Not Apply | CLIA Waived (QW) | No | APC Status Indicator | Service Paid under Fee Schedule or Payment System other than OPPS | Type of Service (TOS) | 5 - Diagnostic Laboratory | Berenson-Eggers TOS (BETOS) | T1H - Lab tests - other (non-Medicare fee schedule) | MUE | 1 |
Date
|
Action
|
Notes
|
---|---|---|
2022-01-01 | Note | Guidelines changed. |
2015-01-01 | Added | Added |
Get instant expert-level medical coding assistance.